Get the Stockscreener App
10.65
0.37%
-0.04
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $10.65, with a volume of 6.37M.
It is down -0.37% in the last 24 hours and up +15.26% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.69
Open:
$10.63
24h Volume:
6.37M
Relative Volume:
0.55
Market Cap:
$12.42B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.3596
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+0.38%
1M Performance:
+15.26%
6M Performance:
-5.33%
1Y Performance:
-8.97%
1-Day Range:
$10.60
$10.82
1-Week Range:
$10.55
$10.82
52-Week Range:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.65 | 12.39B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris' Strategic Leadership Realignment and Long-Term Growth Potential - AInvest
Ex-Dividend Reminder: Evergy, Viatris and CRH - Nasdaq
Stock Analysis | Viatris OutlookMixed Signals Amid Weak Technicals and Strong Fundamentals - AInvest
Q2 Earnings Roundup: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Segment - FinancialContent
Viatris Inc. Appoints Andrew Enrietti as Chief Administrative and Transformation Officer - MarketScreener
Night Vision Disturbances Market to Experience Notable Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris - The Globe and Mail
Lead Plaintiff Appointed in Viatris Class Action — Here’s How You Can Recover Your Losses - TradingView
Viatris names Andrew Enrietti as chief administrative officer - Investing.com
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer - Viatris
Global Healthcare Giant Viatris Creates New C-Suite Role to Drive Digital Transformation Strategy - Stock Titan
Viatris Inc. shares fall 1.79% premarket after Jefferies adjusted price target to $14. - AInvest
Viatris Inc Faces Headwinds: Diminished Financial Strength, Growth, and Valuation Rankings - AInvest
Jefferies Adjusts Price Target on Viatris to $14 From $13, Maintains Buy Rating - MarketScreener
What are the risks of holding Viatris Inc.Weekly Stock Summary & Stock Market Timing Techniques - classian.co.kr
Viatris Inc. Consolidation Zone May Signal Accumulation2025 Market WrapUp & High Conviction Investment Ideas - newsyoung.net
David Einhorn's Greenlight Capital Boosts Fluor Corp, Exits Viatris, Peloton, and Kyndryl - AInvest
Trump EO to bolster stockpile of active pharmaceutical ingredients for drugs - Seeking Alpha
5 Must-Read Analyst Questions From Viatris’s Q2 Earnings Call - Yahoo Finance
Viatris Signals Ongoing Strategic Overhaul, Promises Update In Q3 - insights.citeline.com
Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth - GlobeNewswire Inc.
Day 5 of Gains Streak for Viatris Stock with 19% Return (vs. -14% YTD) [8/13/2025] - Trefis
CEO Makes Bold Move with Major Viatris Stock Purchase - TipRanks
Viatris CEO Smith buys $219k in company stock By Investing.com - Investing.com Nigeria
Viatris CEO Smith buys $219k in company stock - Investing.com India
Viatris CEO Smith Buys 22K Shares at $9.99/Share on August 12, 2023. - AInvest
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - Yahoo Finance
VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds - ca.finance.yahoo.com
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know - Yahoo Finance
Viatris first to win US approval for generic Venofer - The Pharma Letter
Brufen Maker Viatris Fails To Halt Rival's 'Brisen' TM Quest - Law360
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - BioSpace
Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win - simplywall.st
Ampicillin Market Driven by Rising Bacterial Infections - openPR.com
Sector Update: Health Care - MarketScreener
Merz Asks UPC To Bar Viatris Generic MS Drug - Law360
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Viatris Stock Rises 3% After FDA Approval for Generic Iron Sucrose Injection - AInvest
Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance
Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection - MSN
Viatris stock rises after FDA approval of first generic iron sucrose By Investing.com - Investing.com South Africa
Viatris's Generic Iron Sucrose Injection Approval: A Strategic Win for Market Share and Cost-Saving in Healthcare - AInvest
Viatris stock rises after FDA approval of first generic iron sucrose - Investing.com Australia
FDA approves Viatris’ first generic iron sucrose injection for anemia By Investing.com - Investing.com Australia
FDA approves Viatris’ first generic iron sucrose injection for anemia - Investing.com
Viatris announces FDA approval for Iron Sucrose Injection - TipRanks
Viatris Inc. Reports Strong Q2 2025 Results - TipRanks
Carpmaels and A&O Shearman file first SPC suit at UPC for Merz against Viatris - JUVE Patent
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - MSN
Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viatris Inc Stock (VTRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Scott Andrew | Chief Executive Officer |
May 12 '25 |
Buy |
8.94 |
60,000 |
536,262 |
292,807 |
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '25 |
Option Exercise |
0.00 |
41,112 |
0 |
60,441 |
| FINNEY ELISHA W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
37,832 |
| Le Goff Corinne | Chief Commercial Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
37,894 |
0 |
36,721 |
| Campbell Paul | See Remarks |
Mar 04 '25 |
Option Exercise |
0.00 |
207,325 |
0 |
328,250 |
| Campbell Paul | See Remarks |
Mar 03 '25 |
Option Exercise |
0.00 |
19,348 |
0 |
144,590 |
| Vivaldi Coelho Rogerio | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
21,691 |
0 |
21,691 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
0.00 |
96,431 |
0 |
266,825 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
146,700 |
0 |
221,178 |
| PARRISH MARK W | Director |
Mar 04 '25 |
Option Exercise |
0.00 |
18,977 |
0 |
140,395 |
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):